XENE logo

Xenon Pharmaceuticals (XENE) Company Overview

Profile

Full Name:

Xenon Pharmaceuticals Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

November 5, 2014

Indexes:

Not included

Description:

Xenon Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for neurological disorders and pain. They use advanced science to create new medicines that can improve patients' lives. Their goal is to address unmet medical needs and bring effective therapies to market.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 12, 24 HC Wainwright & Co.
Buy
Nov 13, 24 Needham
Buy
Nov 13, 24 HC Wainwright & Co.
Buy
Oct 1, 24 HC Wainwright & Co.
Buy
Sep 3, 24 RBC Capital
Outperform
Aug 12, 24 Needham
Buy
Aug 9, 24 Wedbush
Outperform
Aug 9, 24 Cantor Fitzgerald
Overweight
Jun 18, 24 RBC Capital
Outperform
May 10, 24 Wedbush
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
XENE
seekingalpha.comJanuary 16, 2025

Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time.

Xenon Outlines Key Corporate Milestone Opportunities for 2025
Xenon Outlines Key Corporate Milestone Opportunities for 2025
Xenon Outlines Key Corporate Milestone Opportunities for 2025
XENE
globenewswire.comJanuary 13, 2025

– Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE
zacks.comNovember 13, 2024

XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
XENE
globenewswire.comSeptember 9, 2024

VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster presentations at the 15th European Epilepsy Congress (EEC) taking place in Rome, Italy. Azetukalner, a novel, potent Kv7 channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage development for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS) and major depressive disorder (MDD).

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
XENE
zacks.comAugust 21, 2024

Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
XENE
zacks.comAugust 9, 2024

Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Xenon to Report Q2 2024 Financial Results on August 8, 2024
Xenon to Report Q2 2024 Financial Results on August 8, 2024
Xenon to Report Q2 2024 Financial Results on August 8, 2024
XENE
globenewswire.comAugust 1, 2024

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date: Thursday, August 8, 2024 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963 for international callers Conference ID: 1631616     The live audio webcast can be accessed on the Investors section of the Xenon website.

What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
XENE
Zacks Investment ResearchMay 6, 2024

Xenon Pharmaceuticals (XENE) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
XENE
Zacks Investment ResearchMarch 1, 2024

Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
XENE
Zacks Investment ResearchJanuary 23, 2024

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Xenon Pharmaceuticals?
  • Does Xenon Pharmaceuticals pay dividends?
  • What sector is Xenon Pharmaceuticals in?
  • What industry is Xenon Pharmaceuticals in?
  • What country is Xenon Pharmaceuticals based in?
  • When did Xenon Pharmaceuticals go public?
  • Is Xenon Pharmaceuticals in the S&P 500?
  • Is Xenon Pharmaceuticals in the NASDAQ 100?
  • Is Xenon Pharmaceuticals in the Dow Jones?
  • When was Xenon Pharmaceuticals's last earnings report?
  • When does Xenon Pharmaceuticals report earnings?
  • Should I buy Xenon Pharmaceuticals stock now?

What is the ticker symbol for Xenon Pharmaceuticals?

The ticker symbol for Xenon Pharmaceuticals is NASDAQ:XENE

Does Xenon Pharmaceuticals pay dividends?

No, Xenon Pharmaceuticals does not pay dividends

What sector is Xenon Pharmaceuticals in?

Xenon Pharmaceuticals is in the Healthcare sector

What industry is Xenon Pharmaceuticals in?

Xenon Pharmaceuticals is in the Biotechnology industry

What country is Xenon Pharmaceuticals based in?

Xenon Pharmaceuticals is headquartered in Canada

When did Xenon Pharmaceuticals go public?

Xenon Pharmaceuticals's initial public offering (IPO) was on November 5, 2014

Is Xenon Pharmaceuticals in the S&P 500?

No, Xenon Pharmaceuticals is not included in the S&P 500 index

Is Xenon Pharmaceuticals in the NASDAQ 100?

No, Xenon Pharmaceuticals is not included in the NASDAQ 100 index

Is Xenon Pharmaceuticals in the Dow Jones?

No, Xenon Pharmaceuticals is not included in the Dow Jones index

When was Xenon Pharmaceuticals's last earnings report?

Xenon Pharmaceuticals's most recent earnings report was on Nov 12, 2024

When does Xenon Pharmaceuticals report earnings?

The next expected earnings date for Xenon Pharmaceuticals is Feb 28, 2025

Should I buy Xenon Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions